Therapeutic Management of Nonhospitalized Adults With COVID-19
Ritonavir-Boosted Nirmatrelvir (Paxlovid)
Recommendation
- The Panel recommends using nirmatrelvir 300 mg with ritonavir 100 mg (Paxlovid) orally (PO) twice daily for 5 days in nonhospitalized adults with mild to moderate COVID-19 who are at high risk of disease progression; treatment should be initiated as soon as possible and within 5 days of symptom onset ().
| Ritonavir-Boosted Nirmatrelvir (Paxlovid) | eGFR ≥60 mL/min:
eGFR ≥30 to <60 mL/min:
eGFR <30 mL/min:
Severe Hepatic Impairment (Child-Pugh Class C):
|
≤5 days |
For All Patients:
- All patients should be offered symptom management ().
- The Panel recommends against the use of dexamethasonea or other systemic corticosteroids in the absence of another indication ().
For Patients Who Are at High Risk of Progressing to Severe COVID-19b
Preferred therapies. Listed in order of preference:
- Ritonavir-boosted nirmatrelvir (Paxlovid)c,d ()
- Remdesivird,e ()
Alternative therapies. For use ONLY when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:
- Bebtelovimabf ()
- Molnupiravird,g,h()
Other potential concurrent therapies.
- The Panel recommends against continuing the use of remdesivir, dexamethasonea, or baricitinib () after hospital discharge.
- The Panel recommends against the use of anticoagulants and antiplatelet therapy for the prevention of venous thromboembolism or arterial thrombosis unless the patient has other indications for the therapy or is participating in a clinical trial (). For more information, see Antithrombotic Therapy in Patients With COVID-19.
- The Panel recommends against the use of antibacterial therapy (e.g., azithromycin, doxycycline) for the outpatient treatment of COVID-19 in the absence of another indication ().
Molnupiravir
Recommendations
- The Panel recommends using molnupiravir 800 mg PO twice daily for 5 days as an alternative therapy in nonhospitalized adults with mild to moderate COVID-19 who are at high risk of disease progression ONLY when ritonavir-boosted nirmatrelvir (Paxlovid) and remdesivir are not available, feasible to use, or clinically appropriate; treatment should be initiated as soon as possible and within 5 days of symptom onset ().
- The Panel recommends against the use of molnupiravir for the treatment of COVID-19 in pregnant patients unless there are no other options and therapy is clearly indicated ().